Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference
05/17/2022 - 07:00 AM
NESS ZIONA, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced that that the Company will present at the upcoming H.C. Wainwright Global Investment Conference being held May 23-26, 2022.
Event: H.C. Wainwright Global Investment Conference Date: May 23-26 2022 Format: On-demand presentation and 1:1 meetings Time: Presentation available on-demand beginning Tuesday, May 24th at 7:00 am Eastern Daylight Time Webcast: Link
About Sol-Gel Technologies
Sol-Gel is a dermatology company focused on identifying, developing and commercializing or partnering branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leveraged its proprietary microencapsulation technology platform for TWYNEO® , which is approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, which is approved for the treatment of inflammatory lesions of rosacea in adults. Both drugs are exclusively licensed to Galderma for U.S. commercialization.
The Company’s pipeline also includes early-stage topical drug candidates SGT-210, SGT-310 and SGT-510 under investigation for the treatment of plaque psoriasis and other dermatologic indications.
For further information, please contact:
Investors:
Irina Koffler Investor relations, LifeSci Advisorsikoffler@lifesciadvisors.com +1 917 734 7387
Sol-Gel Technologies
Gilad Mamlok Chief Financial Officergilad.mamlok@sol-gel.com
SLGL Rankings
#5200 Ranked by Stock Gains
SLGL Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Country
Israel
City
7 Golda Meir
About SLGL
sol-gel is a clinical-stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. our lead product candidates, vered for the treatment of papulopustular rosacea and twin and sirs-t for the treatment of acne vulgaris (“acne”) are based upon our proprietary microencapsulation delivery system. this technology consists of microcapsules made of silica. based on our pre-clinical and clinical data, this delivery system should enable us to develop and commercialize dermatological drug products that are more effective and/or have fewer side effects than currently marketed drugs. our silica-based delivery system improves the tolerability of topical dermatological drug products by entrapping drug substances in porous silica microcapsules. this creates a protective barrier between the drug substance and the skin and controls the release rate of the drug substance. our delivery system also enables to produce novel fixed-dose combinations th